Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome  by Marie, I. et al.
Respiratory Medicine (2012) 106, 581e587Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate/rmedRituximab therapy for refractory interstitial lung
disease related to antisynthetase syndromeI. Marie a,*, S. Dominique b, A. Janvresse c, H. Levesque a, J-F. Menard daDepartment of Internal medicine, CHU Rouen, 1 rue de Germont, 76031 Rouen Cedex, France
bDepartment of Pneumology, CHU Rouen, 76031 Rouen Cedex, France
cDepartment of Radiology, CHU Rouen, 76031 Rouen Cedex, France
dDepartment of Biostatistics, CHU Rouen, 76031 Rouen Cedex, France
Received 26 April 2011; accepted 4 January 2012
Available online 24 January 2012KEYWORDS
Polymyositis;
Dermatomyositis;
Antisynthetase
syndrome;
Interstitial lung
disease;
Rituximab* Corresponding author. Tel.: þ33 2
E-mail address: isabelle.marie@ch
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2012.01.001Summary
Objective: To report our experience using rituximab as therapy for refractory antisynthetase
syndrome (ASS)-associated interstitial lung disease.
Methods: We retrospectively evaluated the medical records of 7 ASS patients with refractory
interstitial lung disease, which had previously failed to respond to prednisone and/or other
cytotoxic drugs. All 7 patients received rituximab therapy, i.e.: 1 g at days 0 and 14 and at
6-month follow-up. Data on pulmonary symptoms, pulmonary function tests and high resolu-
tion computed tomography (HRCT) scan of the lungs were collected: 1) before rituximab initi-
ation; and 2) at 6-month and one-year follow-up after the first infusion of rituximab.
Results: At one-year follow-up, ASS patients had resolution (nZ 2) or improvement of pulmo-
nary clinical manifestations. Patients also exhibited significant improvement of interstitial lung
disease parameters: 1) on pulmonary function tests: FVC (pZ 0.03) and DLCO (pZ 2  105);
2) and HRCT-scan of the lungs. Due to clinical resolution/improvement of interstitial lung
disease, the median daily dose of oral prednisone could be reduced in these 7 ASS patients
at one-year follow-up, compared with baseline (20 mg/day vs. 9 mg/day; p Z 0.015).
Conclusion: Our findings suggest that rituximab may be a helpful therapy for refractory inter-
stitial lung disease in patients with ASS.
ª 2012 Elsevier Ltd. All rights reserved.32 88 90 03; fax: þ33 2 32 88 90 26.
u-rouen.fr (I. Marie).
2 Elsevier Ltd. All rights reserved.
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Antisynthetase syndrome (ASS) is characterized by poly-
myositis/dermatomyositis (PM/DM) associated with anti-
synthetase antibodies, arthritis, Raynaud’s phenomenon,
mechanic’s hands and interstitial lung disease (ILD).1 In
patients with ASS, anti-histidyl (anti-Jo1) antibody is the
most common.2e4 Among clinical manifestations, ILD is the
most common complication of ASS, occurring in 70e89% of
patients.5,6 In patients with ASS, ILD has been found to lead
to increased morbidity and mortality.6 To date, the specific
therapy of ILD has not yet been clearly established in
patients with ASS, although corticosteroid therapy is
considered the first-line therapy for these patients.5,6
Favorable outcome with immunosuppressive therapy in
ASS patients who failed to respond to steroids alone has
been reported previously, including cyclophosphamide,
azathioprine, cyclosporine or tacrolimus.5e7
Rituximab is a monoclonal antibody against CD 20 B-
cells, which results in B-cell depletion for at least 6 months.
On the basis of data obtained mainly from case reports,
rituximab has been suggested to be effective in PM/DM
patients who are refractory to other therapies.8e26 Thus,
we have found 53 cases of patients with PM/DM who were
given rituximab for steroid refractory myositis with favor-
able outcome; 10 of these patients exhibited a relapse of
myositis at 8- to 10-month follow-up.8e20 In an open series,
6 patients with refractory DM received rituximab (375 mg/
m2/week for 4 weeks).19 At 3-month follow-up, muscle
strength increased from baseline by 36e113%, and CK
values decreased in all patients; nevertheless, at 52-
month-follow-up, 66% of patients exhibited relapse of DM.19
Recently, in an additional open pilot trial, 13 patients with
refractory PM/DM (including 7 ASS) received rituximab; in
these patients, the median muscle strength improved by
21% and muscle enzyme level (creatine kinase) was reduced
by 93% at 24-month follow-up.20
However, to date, only one retrospective study has
evaluated the efficacy of rituximab therapy in ASS patients
with ILD.27 These data prompted us to conduct the current
study to assess both efficacy and safety of rituximab in 7
ASS patients with severe refractory ILD.
Patients and methods
Patients
Between September 2007 and December 2010, 7 patients
with a diagnosis of ASS and ILD, refractory to conventional
therapies, were included in the study. All 7 patients were
seen at our tertiary referral university medical center. The
diagnosis of PM/DM was based on Bohan and Peter criteria:
1) symmetric muscle weakness; 2) increased serum muscle
enzymes; 3) myopathic changes on electromyography; 4)
typical histologic findings on muscle biopsy; and 5) char-
acteristic dermatologic manifestations. PM and DM were
considered definite in all 7 patients, as they presented at
least four Bohan and Peter criteria.28,29 None of our
patients with ASS had other connective tissue disorders
(especially systemic lupus erythematosus, systemic scle-
rosis, Sjo¨gren’s syndrome or rheumatoid arthritis).The 7 patients with ASS consisted of 3 men and 4 women
with a median age of 57 years [range: 47e59 years]. Six
patients had PM and one patient had DM.
The medical records of the 7 patients were reviewed for
patients’ extra-pulmonary manifestations related to ASS
before rituximab therapy institution, including: 1) muscle
power was gauged by 8 proximal muscles (neck extensors,
trapezius, deltoid, biceps, psoas, maximus and medius
gluteus and quadriceps) by a modification of the British
medical research council grading system, resulting in scores
ranging from 0 to 11 (theoretical maximum score: 88
points); 2) Raynaud’s phenomenon; 3) joint involvement;
and 4) “mechanic’s hands”. Before rituximab therapy
institution, the median level of clinical muscle score was
57.5 points in our patients; 5 patients had arthralgia/
arthritis, 3 had Raynaud’s phenomenon. In addition, 4
patients exhibited mechanic’s hands.
At the beginning of rituximab therapy, laboratory studies
disclosed the following median value for creatine kinase
(CK): 907 IU/L [range: 149-21,460 IU/L]. All patients had
anti-Jo1 antibody; all measurements of serum anti-Jo1
titers had been made in the same universitary Laboratory,
using an automated ELISA (EliA Jo1, Phadia, Germany).
Rituximab therapy
In all 7 ASS patients, ILD manifestations had not responded
to steroids, cytotoxic drugs and/or intravenous immuno-
globulins (IvIG), given for at least 3 months before ritux-
imab initiation. Thus, ILD had, in fact, deteriorated prior to
rituximab therapy institution; furthermore, there had been
no changes in PM/DM therapy (i.e.: steroids and cytotoxic
drugs regimens) in the 2 months before the initiation of
rituximab therapy.
Except prednisone, all other immunosuppressive drugs
were discontinued prior to rituximab therapy initiation. The
decision to initiate rituximab therapy was made after
complete clinical assessment by 2 physicians (IM, SD).
All patients were treated according to the following rit-
uximabprotocol, i.e.: 1) 2 infusionsof 1 g atdays 0and14;and
2) a third infusion of 1 g at 6-month follow-up. The levels of
serumanti-Jo1 titers andbloodCD19 cells (byflowcytometry)
were evaluated before and after rituximab therapy.
This retrospective study was approved by the institu-
tional Ethics committee.
ILD assessment
Before initiation of rituximab therapy, ILD was systemati-
cally investigated by pulmonary function tests and high
resolution computed tomography (HRCT) scan of the lungs.
Pulmonary symptoms
We assessed the following pulmonary clinical symptoms:
dyspnea and cough. The degree of pulmonary symptoms
was evaluated using: 1) NYHA classification for dyspnea;
and 2) visual analog scale for cough. Patients were subse-
quently classified into the 2 following groups according to
ILD presentation: 1) symptomatic acute onset of ILD (taking
the form of antibiotic-resistant immunity-acquired pneu-
monia; 2) symptomatic progressive onset of ILD.
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The PFT parameters assessed were: forced vital capacity
(FVC) and diffusing capacity of carbon monoxide (DLCO).
FVC was measured by spirometry (using a water-sealed
spirometer); the DLCO was obtained by the single-breath
method. Data are expressed as percentages of predicted
values. The predicted values for each subject, based on
sex, age, height and weight, were obtained from stan-
dardized tables.30 Lung function was considered abnormal
when volumes were less than 80% of predicted values and
when DLCO was less than 70% of the predicted value.
High-resolution computed tomography (HRCT) of the
lungs
HRCT of the lungs was performed to assess the presence of
radiographic abnormalities consistent with ILD: paren-
chymal micronodules and nodules, irregular linear opaci-
ties, irregularity of the interfaces between peripheral
pleura and aerated lung parenchyma, ground-glass opaci-
ties, consolidation, honeycombing, and traction bronchi-
ectases or bronchiolectases. HRCT-scan findings were
scored for ground-glass opacities, consolidation and hon-
eycombing, as described previously.31 Findings of HRCT-
scan were analyzed by a radiologist (AJ), who was blinded
to therapy of the 7 ASS patients with refractory ILD.
Previous authors have suggested that HRCT-scan pattern
may be correlated with pulmonary histologic findings, i.e.:
1) cryptogenic organizing pneumonia (COP) is mainly char-
acterized by consolidation and linear opacities; 2)
nonspecific interstitial pneumonia (NSIP) is principally
characterized by ground-glass opacities and irregular linear
opacities; 3) usual interstitial pneumonia (UIP) is mainly
characterized by honeycombing and traction bronchiec-
tases; and 4) diffuse alveolar damage is usually defined by
bilateral and extensive consolidation with airspace and
ground-glass opacities.19e23 Our patients were, in fact,
divided into 4 groups based on HRCT-scan patterns indica-
tive of COP, NSIP, UIP and DAD.6,32e35
Outcome of ILD
Our 7 rituximab-treated ASS patients with ILD were fol-
lowed up for at least 12 months after rituximab initiation.
In the 7 patients, lung investigations were systematically
made to evaluate the outcome of ILD: 1) at 6-month follow-
up (i.e.: 6 months after the 1st rituximab infusion); and 2)
at one-year follow-up (i.e.: one-year after the 1st ritux-
imab infusion). At each visit, patients were assessed by the
same physician (IM, SD).
Thus, the functional disease course for all patients with
ILD was evaluated using validated tools: clinical manifes-
tations, PFT findings and HCRT abnormalities. The
outcomes were categorized as resolution, improvement and
deterioration.
Resolution was defined as complete resolution of
pulmonary symptoms associated with disappearance of
radiographic signs of ILD and normalization of standard PFT
values. Improvement was defined as when any of the
former pulmonary alterations improved without returning
to normal value; according to an international consensus
statement of the American Thoracic Society on idiopathic
pulmonary fibrosis,36 increases of 10% in FVC and/or 15%in DLCO were considered to be significant, and were used as
determinants of improvement. Deterioration was defined as
when any of the features of pulmonary condition worsened
despite institution of therapy; decreases of 10% in FVC
and/or 15% in DLCO were considered to be significant, and
were used as determinant of deterioration.36
Finally, survival status was based on hospital records;
the cause of death was determined through hospital or
physician records.
Statistical analyses
The response to rituximab therapy was analyzed by
comparing changes in pulmonary and extra-pulmonary
outcomes for all patients: at baseline, 6-month and one-
year follow-up after rituximab initiation.
For continuous variables, differences in median values
were calculated at every follow-up visit (i.e.: 6-month and
one-year follow-up) and analyzed for statistical significance
by the Friedman test. In addition, in our rituximab-treated
patients, the Wilcoxon-signed rank test was also used to
compare medians at one-year follow-up with those at
baseline.
Results
Characteristics of ILD before rituximab initiation
ILD onset preceded initial ASS extra-pulmonary clinical
manifestations in 2 patients (6 and 13 months, respec-
tively), and was concurrently identified in association with
ASS in the 5 other patients.
Pulmonary symptoms were recorded in all patients,
which consisted of: 1) dyspnea (n Z 7). According to NYHA
classification, dyspnea was classified as follows: stage II
(nZ 5) and stage III (nZ 2); 2) cough (nZ 5); and 3) fever
(n Z 3). Patients were divided into the 2 following groups
according to their presenting lung manifestations: patients
with symptomatic acute onset of ILD (n Z 2), and patients
with symptomatic progressive onset of ILD (n Z 5).
PFT results were consistent with ILD in all cases. The
median values of PFT parameters were: 66% for FVC [range:
35e76] and 39% for DLCO [range: 20e57]. PFT results indi-
cated severe impairment with DLCO values <45% in 6 of
these 7 patients (without pulmonary arterial hypertension
at echocardiography).
Before initiation of rituximab therapy, HRCT scan of the
lungs demonstrated abnormalities consistent with ILD in all
patients: parenchymal micronodules (n Z 2), linear opac-
ities (n Z 4), irregularity of the interfaces between
peripheral pleura and aerated lung parenchyma (n Z 5),
ground-glass opacities (n Z 6), consolidation (n Z 1),
honeycombing (n Z 2), and traction bronchiectases or
bronchiolectases (n Z 2). Based on pulmonary HRCT-scan
pattern, patients were divided into the following 3 groups:
COP (n Z 1), NSIP (n Z 4) and UIP (n Z 2).
The median interval between ASS-related ILD diagnosis
and rituximab therapy initiation was 12 months [range:
8e60 months] (Table 1). All 7 patients had been given
prednisone therapy from the time of ILD diagnosis and rit-
uximab therapy institution; at rituximab therapy initiation,
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of 20 mg [range: 7e30 mg]. Furthermore, all 7 ASS patients
had ILD that had progressed prior to rituximab therapy
beginning despite ungoing cytotoxic drugs, i.e.: 1) cyclo-
phosphamide and azathioprine (n Z 3); 2) azathioprine
(n Z 1); 3) IvIG (n Z 5); and 4) cyclophosphamide,
azathioprine and mycophenolate mofetil (nZ 2) (Table 1).
The median duration of cytotoxic drug therapy prior to
rituximab initiation was 12 months [range: 6e49 months].
Except prednisone, all other drugs were discontinued prior
to rituximab therapy initiation.
Course of ILD at one-year follow-up
The outcome of our 7 patients with ILD is summarized in
Fig. 1.
Clinical outcome
At one-year follow-up, lung symptoms completely dis-
appeared in 2 of our patients, although these patients
exhibited persistent abnormalities on PFT and HRCT of the
lungs. The 5 other rituximab-treated patients also experi-
enced improvement of clinical pulmonary manifestations
related to ILD; in these patients, pulmonary symptoms were
as follows: dyspnea (n Z 3: stage II according to NYHA
classification) and cough (n Z 2).
PFTs findings
To assess changes in pulmonary function over time, we
compared the findings of FVC and DLCO measurement, prior
to rituximab and 6-month and 12-month after rituximab
initiation. As shown in Fig. 1A and B, rituximab-treated
patients exhibited significant improvement of FVC
(p Z 0.03) and DLCO (p Z 2 105) values over time. Thus,
patients exhibited higher median values of FVC and DLCO at
one-year follow-up compared with baseline, i.e.: 1) the
median level of FVC increased from 66% [range: 35e76] to
74% [range: 57e108] (pZ 0.04); and 2) the median level of
DLCO increased from 39% [range: 20e57] to 59% [range:
49e72] (p Z 0.001).
HRCT-scan data
At one-year follow-up, HRCT-scan of the lungs showed
improvement of ILD abnormalities without reaching normal
limits in the 5 ASS patients, i.e.: 1) regression ofTable 1 Demographic characteristics, prior and concurrent th
with rituximab.
Patient/Age/Sex PD/DMa subset Prior therapies
1/59/F PM Preda, CYCa, AZAa, IvIGa
2/57/M PM Pred, AZA
3/59/M DM Pred, CYC, AZA, IvIG
4/56/F PM Pred, AZA, MMFa
5/47/F PM Pred, CYC, AZA, IvIG, MM
6/58/M PM Pred, CYC, AZA, IvIG, MM
7/54/F PM Pred, CYC, AZA, IvIG
a ASS: antisynthetase syndrome; PM/DM: polymyositis/dermatomyo
prine; IvIG: intravenous immunoglobulins; MMF: mycophenolate mofeconsolidation (n Z 1), ground-glass opacities (n Z 1),
parenchymal micronodules (n Z 1) and irregularity of the
interfaces (n Z 1); and 2) decrease of ground-glass opaci-
ties (n Z 3); and 3) improvement of: linear opacities and
irregularity of interfaces (n Z 3), and parenchymal micro-
nodules (n Z 1).
The 2 remaining patients had no progression of ILD at
one-year follow-up, i.e.: 1) areas with honeycombing
(n Z 2) remained unchanged; and 2) linear opacities
(n Z 1), irregularity of the interfaces (n Z 1) and ground-
glass opacities (n Z 2) also remained unchanged.
Concomitant steroid therapy
Due to clinical resolution/improvement of ILD in rituximab-
treated patients, the daily dose of oral prednisone was
gradually tapered (p Z 5 105). Indeed, the median daily
dose of prednisone could be decreased from 20 mg [range:
7e30 mg] at baseline to 9 mg [range: 3e15 mg] at one-year
follow-up (p Z 0.015).
Finally, none of our 7 rituximab-treated ASS patients
with ILD had died at one-year follow-up.
Course of other manifestations at one-year follow-
up
Muscle strength
In our 7 patients, the median value of muscle strength score
significantly improved, compared with baseline, at 6-month
and one-year follow-up (p Z 0.001). Interestingly,
a complete clinical response was achieved in 2 patients who
exhibited normalmuscle strength scores. As shown in Fig. 1C,
the median value of muscle strength score increased from
57.5 points [range: 45e73] before rituximab therapy to 79
points [range: 69e88] at one-year follow-up (pZ 0.01).
Other clinical manifestations
At one-year follow-up, joint involvement resolved (n Z 1)
or improved (n Z 4) in our rituximab-treated patients.
Furthermore, all patients exhibited complete disappear-
ance of cutaneous manifestations related to ASS (i.e.:
mechanic’s hands).
CK levels
In all patients, the median CK level significantly
decreased, compared with baseline, at every time pointerapies, and daily prednisone doses in ASS* patients treated
ILD duration prior
to rituximab therapy (months)
Prednisone (mg/day)
At start At 1-year
12 17.5 10
11 7 5
16 30 3
8 15 8
F 60 20 9
F 9 25 15
37 22.5 12.5
sitis; Pred: prednisone; CYC: cyclophosphamide; AZA: azathio-
til.
Figure 1 Assessment in ASS* patients after rituximab therapy. A: forced vital capacity (FVC) values on pulmonary function tests
(PFT). B: diffusing capacity of carbon monoxide (DLCO) values on PFT. C: muscle strength. D: Creatine kinase (CK) levels. E: CD19-
positive B-cell count; *ASS: antisynthetase syndrome. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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rituximab therapy initiation in 3 patients. As shown in
Fig. 1D, the median level of CK decreased from 907 IU/L
[range: 149-21,460 IU/L] prior to rituximab therapy to
196 IU/L at one-year follow-up [range: 35e711 IU/L]
(p Z 0.012).
Anti-Jo1 antibody
Longitudinal data on serum anti-Jo1 antibody levels were
available in all 7 rituximab-treated patients. Thus, the
median level of anti-Jo1 antibody decreased from 412
U/mL [range: 77e479 U/mL] at baseline to 87 U/mL [range:
54e316 U/mL] at one-year follow-up (p Z 0.01).
CD19-positive B cells
Rituximab-treated patients exhibited a complete CD19-
positive B-cell depletion over time (p Z 0.001). As shown
in Fig. 1E, patients had a marked decrease of CD19 þ B-cell
median count at one-year follow-up compared with base-
line (p Z 0.015).Safety of rituximab therapy
No patient experienced opportunistic or severe pyogenic
infection during the follow-up period.Discussion
Many authors have reported a poorer prognosis for patients
with ASS, compared with other PM/DM patients; in the
majority of these ASS patients, poorer prognosis was, in
fact, related to severe ILD.5,6 However, because ASS is an
uncommon condition, it is difficult to study this orphan
disease in a randomized controlled fashion. Indeed, the
optimal management of ILD in ASS patients is still not
established.6 Current therapy is based on the use of
steroids.5,6 In patients who failed to respond to steroids
alone, favorable outcome has also been reported after
institution of immunosuppressive therapy, including cyclo-
phosphamide, azathioprine, cyclosporine, mycophenolate
586 I. Marie et al.mofetil or tacrolimus.5e7 Unfortunately, these therapies
are not always effective in ASS patients with severe ILD.
The need for effective therapy has prompted some inves-
tigators to evaluate the efficacy of rituximab therapy in
patients with refractory PM/DM; on the basis of a number of
case reports’ data, rituximab has, in fact, been suggested
to be effective in PM/DM patients with refractory PM/
DM.8e26
However, to date, only few investigators have examined
the efficacy of rituximab in PM/DM patients with refractory
pulmonary involvement. Gheita et al37 reported a PM
patient with refractory severe ventilatory insufficiency due
to respiratory striated muscle weakness; he successfully
received rituximab treatment. Lee et al38 also described
a patient with refractory DM and spontaneous pneumo-
mediastinum who was given rituximab treatment; the
patient exhibited marked improvement of pulmonary status
at 3-month follow-up.
Furthermore, in our literature review of Medline data-
base (1966e2011), we have only found 13 cases of patients
with refractory PM/DM and ILD who received rituximab
therapy.27,39,40 Vandenbroucke et al39 described an adult
ASS patient with severe steroid- and cyclophosphamide-
refractory ILD who received rituximab treatment; he
exhibited improvement of ILD (with decreased oxygen
need) after two sequential rituximab infusions. Yanez
et al40 also reported a DM patient who developed refractory
chronic organizing pneumonia; in this patient, rituximab
led to improvement of lung symptoms and abnormalities on
HRCT-scan. Finally, an open trial has suggested that ritux-
imab may be useful in PM/DM-related ILD at short-term
follow-up; 11 ASS patients with ILD received rituximab,
which resulted in improvement of ILD in 64% of cases at 6-
month follow-up.27
In this instance, rituximab therapy was also a helpful
therapy in our 7 ASS patients with refractory ILD as: 1) we
have shown a significant improvement of ILD using vali-
dated methods to assess lung condition, i.e.: lung symp-
toms, PFTs and HRCT-scan findings; 2) the daily dose of oral
prednisone could be gradually tapered in all patients; and
3) no patient received additional cytotoxic drugs concur-
rently. Our 7 patients were followed up for one-year;
indeed, the duration period of follow-up in our series was
longer than that of Sem et al’s series.27 Interestingly, we
have also observed that our 7 rituximab-patients concur-
rently exhibited: 1) marked improvement of muscle and
cutaneous manifestations of ASS; and 2) significant
decrease of anti-Jo1 antibody over time. Our later findings,
in fact, suggest that anti-Jo1 level may be correlated with
ASS and ILD activity.
Thus, we believe that the current study adds to the
knowledge about the efficacy of rituximab in ASS patients
with refractory ILD. The strengths of our study are that: 1)
all ASS patients with ILD underwent a standardized long-
term follow-up; and 2) there was no concurrent bias related
to additional or increased doses of concurrent steroid/
immunosuppressive therapy during the study period.
Nevertheless, our study has limitations, including: 1) the
retrospective and uncontrolled nature of our series; 2) the
small number of patients, including mainly patients with PM
(n Z 6/7); and 3) the heterogeneity of ILD characteristics,
especially regarding ILD duration prior to rituximab therapyinitiation [range: 8e60 months]. In essence, further
controlled investigations are required to confirm our
promising findings in a larger cohort of ASS patients with
ILD.
Taken together, the results of our study indicate that
rituximab could be included in the therapeutic approach to
ASS patients with severe refractory ILD. However, further
investigation is required to confirm our data and to estab-
lish optimal management in this patient population.Conflict of interest
None declared.References
1. Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmo-
nary fibrosis and autoantibodies to aminoacyl-tRNA synthetase
enzymes. Q J Med 1990;77:1019e38.
2. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N.
Anti-synthetase syndrome: a new autoantibody to phenylalanyl
transfer RNA synthetase (anti-Zo) associated with polymyositis
and interstitial pneumonia. Rheumatology (Oxford) 2007;46:
1005e8.
3. Hervier B, Uzunhan Y, Hachulla E, et al. Antisynthetase
syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7)
antibodies. Eur Respir J 2011;37:714e7.
4. Hirakata M, Suwa A, Nagai S, et al. Anti-KS: identification of
autoantibodies to asparaginyl-transfer RNA synthetase associ-
ated with interstitial lung disease. J Immunol 1999;162:
2315e20.
5. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Inter-
stitial lung disease associated with the idiopathic inflammatory
myopathies. What progress has been made in the past 35 years?
Chest 2010;138:1464e74.
6. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L,
Menard JF. Short term and long term outcome of interstitial
lung disease in polymyositis and dermatomyositis: a series of
107 patients. Arthritis Rheum 2011;63:3439e47.
7. Marie I, Mouthon L. Therapy of polymyositis and dermato-
myositis. Autoimmun Rev 2011 Jun 28 [Epub ahead of print].
8. Andres M, Courtney P. No hepatitis B reactivation in a patient
with refractory antisynthetase syndrome successfully treated
with rituximab. Jt Bone Spine 2011 Jul 30 [Epub ahead of
print].
9. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treat-
ment of antisynthetase syndrome. Ann Rheum Dis 2006;65:
974e5.
10. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment
of refractory dermatomyositis. J Clin Rheumatol 2005;11:
264e6.
11. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab
in the treatment of patients with dermatomyositis. Arch Der-
matol 2007;143:763e7.
12. Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the
treatment of the skin manifestations of dermatomyositis:
a report of 3 cases. J Am Acad Dermatol 2007;56:148e53.
13. Feist E, Do¨rner T, So¨rensen H, Burmester GR. Longlasting
remissions after treatment with rituximab for autoimmune
myositis. J Rheumatol 2008;35:1230e2.
14. Frikha F, Rigolet A, Behin A, Fautrel B, Herson S, Benveniste O.
Efficacy of rituximab in refractory and relapsing myositis with
anti-JO1 antibodies: a report of two cases. Rheumatology
(Oxford) 2009;48:1166e8.
Rituximab therapy for refractory interstitial lung disease 58715. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and
short term efficacy of rituximab in 43 patients with systemic
autoimmune diseases. Ann Rheum Dis 2005;64:913e20.
16. Jois R, Vasudevan N, Srinivasan P, Mehta R. Resistant derma-
tomyositis complicated by tubercular myositis and successfully
treated with rituximab. Neurol India 2011;59:306e7.
17. Joshi N, Nautiyal A, Davies PG. Successful use of rituximab in
recalcitrant skin predominant dermatomyositis. J Clin Rheu-
matol 2011;17:111e2.
18. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C,
Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J
Rheumatol 2005;32:1369e70.
19. Levine TD. Rituximab in the treatment of dermatomyositis: an
open-label pilot study. Arthritis Rheum 2005;52:601e7.
20. Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL,
Vonk MC. Rituximab treatment in patients with refractory
inflammatory myopathies. Oxford: Rheumatology; 2011 May 13
[Epub ahead of print].
21. Majmudar S, Hall HA, Zimmermann B. Treatment of adult
inflammatory myositis with rituximab: an emerging therapy for
refractory patients. J Clin Rheumatol 2009;15:338e40.
22. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an
open-label prospective study. J Rheumatol 2007;34:1864e8.
23. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as
therapy for refractory polymyositis and dermatomyositis. J
Rheumatol 2006;33:1021e6.
24. Sa´nchez-Ramo´n S, Ravell JC, de la Torre I, et al. Long-term
remission of severe refractory dermatopolymyositis with
a weekly-scheme of immunoglobulin followed by rituximab
therapy. Rheumatol Int 2010;30:817e9.
25. Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G.
Clinical outcome following B cell depletion therapy in eight
patients with refractory idiopathic inflammatory myopathy.
Clin Exp Rheumatol 2008;26:887e93.
26. Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of
cardiac involvement in dermatomyositis with rituximab. Jt
Bone Spine 2008;75:334e7.
27. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of
the anti-synthetase syndrome: a retrospective case series.
Rheumatology (Oxford) 2009;48:968e71.
28. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J
Med 1975;292:344e7.29. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J
Med 1975;292:403e7.
30. Quanjer PH. Clinical respiratory physiology: standardized lung
function testing: working party report: standardization of lung
function tests. Bull Eur Physiopathol Respir 1983;19(Suppl. 5):
1e95.
31. Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT
findings in interstitial lung disease associated with poly-
myositis-dermatomyositis. Eur J Radiol 2004;49:235e44.
32. Cottin V, Thivolet-Be´jui F, Reynaud-Gaubert M, et al. Inter-
stitial lung disease in amyopathic dermatomyositis, dermato-
myositis and polymyositis. Eur Respir J 2003;22:245e50.
33. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB,
Colby TV, et al. Radiological versus histological diagnosis in UIP
and NSIP: survival implications. Thorax 2003;58:143e8.
34. Schmidt SL, Sundaram B, Flaherty KR. Diagnosing fibrotic lung
disease: when is high-resolution computed tomography suffi-
cient to make a diagnosis of idiopathic pulmonary fibrosis?
Respirology 2009;14:934e9.
35. Shin KM, Lee KS, Chung MP, Han J, Bae YA, Kim TS, et al.
Prognostic determinants among clinical, thin-section CT, and
histopathologic findings for fibrotic idiopathic interstitial
pneumonias: tertiary hospital study. Radiology 2008;249:
328e37.
36. American Thoracic Society. Idiopathic pulmonary fibrosis:
diagnosis and treatment. International consensus statement.
American Thoracic Society (ATS), and the European respiratory
Society (ERS). Am J Respir Crit Care Med 2000;161:646e64.
37. Gheita TA, Gheita HA, Kenawy SA. Rituximab restored the
muscle power and rescued from a refractory fatal respiratory
failure in a patient with elderly-onset polymyositis. Joint
Bone Spine; 2011 Aug 11 [Epub ahead of print].
38. Lee MA, Hutchinson DG. Spontaneous pneumomediastinum
secondary to refractory dermatomyositis successfully treated
with rituximab. Clin Rheumatol 2010;29:945e6.
39. Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, ter
Borg EJ, van den Bosch JM. Rituximab in life threatening
antisynthetase syndrome. Rheumatol Int 2009;29:1499e502.
40. Ya´n˜ez VJ, Cisternas MM, Saldı´as HV, Saldı´as PF. Refractory
dermatomyositis associated with chronic organizing pneu-
monia treated with rituximab: report of one case. Rev Med Chil
2009;137:88e93.
